FDA Opens Early Access to Novel Pancreatic Cancer Drug Generating Buzz
Summary
Requests for treatment with daraxonrasib must come from licensed U.S. physicians
Original reporting
Open original sourceAFBytes is a read-only aggregator. Use the original source for full context and complete reporting.